Sienna has signed a binding agreement to purchase the intellectual property assets of California-based Sevident Inc, marking Sienna’s first transaction in its technology expansion strategy and a new opportunity to generate future revenue...
Read More »Integrated analysis of exosomal protein biomarkers on A/C electrokinetic chips
Pancreatic ductal adenocarcinoma (PDAC) typically has nonspecific symptoms and is often found too late to treat. Because diagnosis of PDAC involves complex, invasive, and expensive procedures, screening populations at increased risk will depend on...
Read More »Microfluidics technologies for blood-based cancer liquid biopsies
Blood-based liquid biopsies provide a minimally invasive alternative to identify cellular and molecular signatures that can be used as biomarkers to detect early-stage cancer, predict disease progression, longitudinally monitor response to chemotherapeutic drugs, and provide personalized treatment options. Specific targets ...
Read More »Targeting Malicious Exosomes with Gold Nanoparticles for Cancer Therapy
Exosomes are nanovesicles formed in the endosomal pathway with an important role in paracrine and autocrine cell communication. Exosomes secreted by cancer cells, malicious exosomes, have important roles in tumor microenvironment maturation and cancer progression. The knowledge of the role ...
Read More »Liquid Biopsy Cancer Diagnostics Market – Anticipated to Grow Aggressively at 44% CAGR
Liquid biopsy primarily focuses on the detection, isolation and characterization of biomarkers from circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) or exosomes present in biological fluids, which can be collected in a single blood draw. Primarily driven by liquid ...
Read More »Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsies
Sequencing genetic material from liquid biopsies promises to be one of the most important recent developments in cancer diagnostics. The relative ease and minimally invasive nature of obtaining liquid biopsies makes it an attractive alternative source of tumor DNA relative ...
Read More »Exosomes Offer Huge Potential for Cancer Diagnostics
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Exosome Diagnostics and Therapeutics: Global Markets” report to their offering. The global market for exosome diagnostics and therapeutics is projected to grow from $16.1 million in 2016 to $111.8 million ...
Read More »Using Circulating Biomarkers for Cancer Diagnostics Development
from Genetic Engineering News by Enal Razvi There is increasing interest in the potential of circulating biomarker classes as a means to developing minimally invasive biopsies primarily for cancer but with penetrance into many other disease classes such as CNS ...
Read More »Benchtop isolation and characterization of functional exosomes by sequential filtration
Early and minimally invasive detection of malignant events or other pathologies is of utmost importance in the pursuit of improved patient care and outcomes. Recent evidence indicates that exosomes and extracellular vesicles in serum and body fluids can contain nucleic ...
Read More »